Raymond James & Associates Raises Holdings in uniQure (NASDAQ:QURE)

Raymond James & Associates increased its position in uniQure (NASDAQ:QURE) by 6.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 52,224 shares of the biotechnology company’s stock after buying an additional 3,145 shares during the quarter. Raymond James & Associates’ holdings in uniQure were worth $354,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in QURE. Barclays PLC raised its position in shares of uniQure by 527.8% in the 3rd quarter. Barclays PLC now owns 989,562 shares of the biotechnology company’s stock worth $6,641,000 after buying an additional 831,929 shares during the period. Citigroup Inc. increased its holdings in uniQure by 667.9% in the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after purchasing an additional 666,696 shares in the last quarter. Algert Global LLC increased its holdings in uniQure by 237.6% in the 3rd quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company’s stock valued at $2,780,000 after purchasing an additional 291,541 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of uniQure by 21.6% during the third quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock valued at $10,568,000 after acquiring an additional 280,000 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its stake in shares of uniQure by 97.3% during the third quarter. Rafferty Asset Management LLC now owns 390,844 shares of the biotechnology company’s stock valued at $2,623,000 after acquiring an additional 192,785 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on QURE shares. Royal Bank of Canada restated an “outperform” rating and set a $28.00 target price on shares of uniQure in a research note on Tuesday, January 16th. Mizuho lowered their target price on uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Monday, March 4th. HC Wainwright lowered their target price on uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, March 1st. StockNews.com upgraded uniQure to a “sell” rating in a research note on Friday, March 1st. Finally, The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $63.00 to $8.00 in a research note on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $4.53 on Monday. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49. The firm’s 50-day moving average price is $5.27 and its two-hundred day moving average price is $5.98. uniQure has a 52-week low of $4.35 and a 52-week high of $22.48. The stock has a market capitalization of $216.71 million, a P/E ratio of -0.70 and a beta of 0.95.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The firm had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $3.20 million. As a group, sell-side analysts forecast that uniQure will post -4.49 earnings per share for the current year.

Insider Activity

In other news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at $554,110.21. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at $554,110.21. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the sale, the chief executive officer now directly owns 440,839 shares in the company, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,265 shares of company stock valued at $339,845. Insiders own 4.05% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.